Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America

Date
2014-05-01Author
Condino-Neto, A.
Costa-Carvalho, B. T. [UNIFESP]
Grumach, A. S.
King, A.
Bezrodnik, L.
Oteastro, M.
Leiva, L.
Porras, O.
Espinosa-Rosales, F. J.
Franco, J. L.
Sorensen, R. U.
Type
ArtigoISSN
0301-0546Is part of
Allergologia Et ImmunopathologiaDOI
10.1016/j.aller.2012.09.006Metadata
Show full item recordAbstract
Antibodies are an essential component of the adaptative immune response and hold long-term memory of the immunological experiences throughout life. Antibody defects represent approximately half of the well-known primary immunodeficiencies requiring immunoglobulin replacement therapy. in this article, the authors review the current indications and therapeutic protocols in the Latin American environment. Immunoglobulin replacement therapy has been a safe procedure that induces dramatic positive changes in the clinical outcome of patients who carry antibody defects. (C) 2012 SEICAP Published by Elsevier Espana, S.L. All rights reserved.
Citation
Allergologia Et Immunopathologia. Barcelona: Elsevier Doyma Sl, v. 42, n. 3, p. 245-260, 2014.Keywords
Immunoglobulin replacement therapyIntravenous immunoglobulin
Subcutaneous immunoglobulin
Guidelines
Primary immunodeficiency
Latin America
Collections
- EPM - Artigos [17701]